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Much is known about the transport of arsenite and antimonite into
microbes, but the identities of mammalian transport proteins are
unknown. The Saccharomyces cerevisiae FPS1 gene encodes a
membrane protein homologous to the bacterial aquaglyceroporin
GlpF and to mammalian aquaglyceroporins AQP7 and AQP9. Fps1p
mediates glycerol uptake and glycerol efflux in response to hy-
poosmotic shock. Fps1p has been shown to facilitate uptake of the
metalloids arsenite and antimonite, and the Escherichia coli ho-
molog, GlpF, facilitates the uptake and sensitivity to metalloid
salts. In this study, the ability of mammalian aquaglyceroporins
AQP7 and AQP9 to substitute for the yeast Fps1p was examined.
The fps1 strain of S. cerevisiae exhibits increased tolerance to
arsenite and antimonite compared to a wild-type strain. Introduc-
tion of a plasmid containing AQP9 reverses the metalloid tolerance
of the deletion strain. AQP7 was not expressed in yeast. The fps1
cells exhibit reduced transport of 73As(III) or 125Sb(III), but uptake
is enhanced by expression of AQP9. Xenopus laevis oocytes mi-
croinjected with either AQP7 or AQP9 cRNA exhibited increased
transport of 73As(III). These results suggest that AQP9 and AQP7
may be a major routes of arsenite uptake into mammalian cells, an
observation potentially of large importance for understanding the
action of arsenite as a human toxin and carcinogen, as well as its
efficacy as a chemotherapeutic agent for acute promyelocytic
leukemia.
Fps1p  GlpF  acute promyelocytic leukemia
The U.S. Environmental Protection Agency has classifiedarsenic as a human carcinogen (1). Conversely trivalent
arsenic is an effective chemotherapeutic agent for the treatment
of acute promyelocytic leukemia (2). For a complete under-
standing of the mechanisms of arsenic toxicity and carcinogen-
esis as well as its ability to serve as a chemotherapeutic agent, it
is necessary to identify the routes of arsenite uptake and efflux
from cells (3, 4). Arsenic is bioavailable in either of two oxidation
states, As(V) (arsenate) or As(III) (arsenite). Pentavalent ar-
senic is transported into cells via phosphate transport systems in
both prokaryotes (5) and eukaryotes (6). It is reduced to the
more toxic trivalent arsenite by arsenate reductases (7–9).
Arsenite can be detoxified either by extrusion from cells or by
sequestration within intracellular organelles as thiol conjugates
(3, 4, 10). In Saccharomyces cerevisiae, Acr3p is an arsenite
extrusion system (11, 12), and the ABC transporter Ycf1p
catalyzes uptake of As(GS)3 into the vacuole (12).
The routes of uptake of arsenite are less well defined. In
Escherichia coli, we showed that disruption of the glpF gene led
to increased tolerance for antimonite, which is chemically similar
to arsenite (13). GlpF facilitates glycerol uptake (14, 15) and is
a bacterial member of the aquaporins, a family of membrane
proteins that includes water-selective pores (aquaporins) and
multifunctional channels (aquaglyceroporins), which also trans-
port organic polyols and urea (16). It is likely that GlpF
recognizes the un-ionized form of antimonite, Sb(OH)3, trans-
porting it as the inorganic equivalent of a polyol. With a pKa of
11.8, this protonated form would predominate in neutral solu-
tions. Although the glpF mutant did not exhibit increased
arsenite tolerance, we postulated that GlpF also transports
As(OH)3, the primary ionization state of arsenite in neutral
solutions, but that redundancy in arsenic transporters dampens
the effect of the glpF mutation (13). Recently the GlpF homolog
Fps1p, a S. cerevisiae aquaglyceroporin (17), was clearly shown
to be involved in uptake of arsenite (18). Deletion of the FPS1
gene resulted in increased tolerance to both arsenite and anti-
monite, and fps1 cells exhibited decreased uptake of radioac-
tive arsenite. Although E. coli GlpF has a physiological role for
uptake of glycerol, yeast Fps1p functions primarily as a glycerol
eff lux pathway for osmoregulation (19).
The transporters for uptake of arsenite and antimonite into
mammalian cells are unknown. Passive permeability of the
neutral As(OH)3 and Sb(OH)3 species is energetically unfavor-
able, implying that one or more transport proteins must exist.
Given the ubiquity of aquaglyceroporins and their ability to
transport arsenite into microorganisms, it was reasonable to
investigate the metalloid transport properties of mammalian
aquaglyceroporins. The mammalian aquaglyceroporin subfamily
includes AQP3, AQP7, and AQP9, of which AQP9 has broadest
solute permeability (16). In this report the Rattus norvegicus
AQP9 (20) cDNA was cloned into an S. cerevisiae expression
vector under control of the GAL4 promoter, and its ability to
substitute for Fps1p in metalloid uptake was examined. A strain
of S. cerevisiae was constructed from which the genes encoding
FPS1 and the two arsenite eff lux transporters, Acr3p and Ycf1p,
were deleted. Compared with a wild-type strain, an acr3 ycf1
strain is hypersensitive to both arsenite and antimonite (12).
Deletion of FPS1 in the acr3 ycf1 strain increased tolerance
to both metalloids, in agreement with the results of Wysocki et
al. (18). Galactose-inducible expression of membrane-bound
AQP9 was observed, and AQP9 expression made the triple
deletion strain more sensitive to arsenite and antimonite in a
galactose-dependent fashion. Cells of the acr3 ycf1 strain
accumulate more 73As(OH)3 than a wild-type strain because they
are unable to extrude arsenite (12). Cells of the fps1 acr3
ycf1 strain accumulated less arsenite than the acr3 ycf1
strain, consistent with Fps1p facilitating arsenite uptake (18).
AQP9 expression resulted in increased transport of both
73As(OH)3 and 125Sb(OH)3, demonstrating that AQP9 can func-
tionally substitute for Fps1p in the transport of metalloids. In
contrast, when the Mus musculus AQP7 cDNA was cloned into
the same yeast vector, no AQP7 was expressed. However,
Xenopus oocytes microinjected with either AQP7 or AQP9
cRNA exhibited a 10-fold increase in 73As(OH)3 permeability,
indicating that both aquaglyceroporins recognize and transport
arsenite.
Materials and Methods
Strains and Plasmids. Plasmids and S. cerevisiae strains used in this
study are described in Table 1. E. coli strain JM109 [recA1
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supE44 endA1 hsdR17 gyrA96 relA1 thi (lac-proAB) F (traD36
proAB lacIq lacZM15] and JM110 [rps (Strr) thr leu thi-1 lacY
galK galT ara tonA tsx dam dcm supE44 (lac-proAB) [F traD36
proAB lacIqZM15] were used for molecular cloning.
Media. S. cerevisiae strains were grown at 30° C in complete yeast
extract-peptone-dextrose (2%) or yeast extract-peptone-glycerol
(2%) medium (21). Alternatively, the minimal SD medium
(composition of the medium may be found in ref. 21) supple-
mented with either 2% galactose or 2% glucose and with
auxotrophic requirements. E. coli cells were grown in LB
medium (22) supplemented when necessary with 125 gml
ampicillin.
DNA Manipulations. Plasmid purification, restriction digestion,
endonuclease and exonuclease digestions, gel electrophoresis,
PCR, ligation, dephosphorylation, and E. coli transformations
were carried out as described (22, 23). Transformation of yeast
cells was carried out by using a Geno easy-transform kit (Geno
Technologies, St. Louis, MO). Yeast genomic DNA was isolated
by using QIAamp spin column according to the manufacturer’s
directions (Qiagen).
Deletion of the FPS1 Gene. The FPS1 gene was deleted by a
one-step gene replacement method (24). A 1,941-bp fragment of
yeast genomic DNA containing FPS1 was PCR amplified with a
forward primer 5-ATGAGTAATCCTCAAAAAGC-3 that
hybridizes with the start of the FPS1 gene and a reverse primer
5-TCATGTTACCTTCTTAGC-3 that hybridizes to the end of
the coding sequence. The fragment was ligated into vector
pGEM-T and transformed into E. coli JM110. The resulting
plasmid, pGEM-T-FPS1, was isolated and digested with StuI,
which produced a 1,245-bp fragment that was 427 bp from the
start and 269 bp from the end of the FPS1 gene. The 3-kbp LEU2
gene was isolated from plasmid pUC18-LEU2 by digestion with
PstI and AlwNI to cut out the LEU2 gene and with SmaI to digest
the remaining vector DNA. The FPS1 and LEU2 fragments were
ligated together, and the resulting plasmid was digested with PstI
and SphI. The 3.7-kbp fragment was isolated, purified, and
transformed into yeast strain MG102 (acr3 ycf1), producing
the fps1 acr3 ycf1 strain HD9 by homologous recombination.
Recombinants were selected for growth in the absence of leucine
and were screened for arsenite sensitivity. Deletion of FPS1 was
verified by PCR by using the forward and reverse primers
described above.
Cloning AQP7 and AQP9 into the S. cerevisiae Expression Vector
pYES3. AQP7 cDNA was amplified by reverse transcription–PCR
of mouse adipocyte total RNA by using forward primer
5-GGGGAATTCAGATCTATGGCCCCCAGGTCTGT-
GCTG-3 and reverse primer 5-GGGGAATTCAGATCTT-
TAGAAGTGCTCTAGAGGCAC-3. AQP9 cDNA was ampli-
fied by reverse transcription–PCR from rat liver total RNA
from Ambion by using a forward 5-GGGAGATCTGAAT-
TCATGCCTTCTGAGAAGGACGGTGC-3 and reverse
primer 5-GGGAGATCTGAATTCCTACATGATGACA-
CTGAGCTCG-3. PCR products were digested with BglII and
cloned into BglII-digested vector pXG-ev1, producing plasmids
pXG-ev1-AQP7 and pXG-ev1-AQP9. The AQP7 and AQP9
genes were sequenced, and an A93V polymorphism was found in
AQP9, which was corrected to the published Ala-93 by site-
directed mutagenesis. Plasmid pXG-ev1-AQP9 was digested
with HindIII and KpnI. A 1.1-kbp fragment containing the AQP9
gene was ligated into HindIII–KpnI digested plasmid pYES3.
The ligation mixture was transformed into E. coli strain JM109,
and the resulting plasmid, pAQP9, was isolated and transformed
into yeast strain HD9. The transformants were selected on
minimal SD medium without tryptophan. Plasmid pAQP7 was
prepared similarly. Plasmid pXG-ev1-AQP7 was digested with
HindIII and SpeI. The linearized 1.2-kbp fragment containing
AQP7 was made blunt by using large fragment of DNA poly-
merase I. Vector plasmid was digested with EcoRI, and the ends
were made blunt by using large fragment of DNA polymerase I.
The two blunt-end DNAs were ligated together, and the ligation
mixture was transformed into E. coli strain JM109. A plasmid
with the correct insert, termed pAQP7, was isolated and trans-
formed into yeast strain HD9. The transformants were selected
on minimal SD medium without tryptophan. The constructs for
pAQP7 and pAQP9 were sequenced to confirm that they
retained the reported DNA sequences.
Metal Ion Resistance Assays. Strains were grown overnight at 30°C
in liquid SD medium with either 2% glucose or 2% galactose and
the appropriate supplements. The cultures were diluted into
minimal media to an OD600 of 0.1 in presence of varying
concentrations of the indicated metalloid salts, incubated for an
additional 20 h, following which the growth was estimated from
OD600. For growth on solid media, cells were streaked from
single colonies and incubated for 3–4 d at 30°C.
Transport Assays. In vivo metalloid uptake assays were performed
as described (12). In brief, cells were grown to exponential phase
Table 1. Strains and plasmids
Strainsplasmids Genotypedescription Source
S. cerevisiae strains
W303-1B MAT ade2-1 his3-11,15 leu2-3,112 ura3-1 trp-1 Ref. 44
DTY167 MAT ura3-52 his6 leu2-3,112 his3-,200 trp1-901 lys2-80 suc2̄ycf1hisG Ref. 45
MG102 MAT ura3-52 his6 leu2-3,112 his3-,200 trp1-901 lys2-801 suc2̃ycf1hisG acr3URA3 Ref. 12
HD9 MAT ura3-52 his6 leu2-3,112 his3-,200 trp1-901 lys2-801 suc2̃ycf1hisG acr3URA3 fps1leu2 This study
Plasmids
pGEM-T E. coli cloning vector, Apr Promega
pYES3 S. cerevisiae–E. coli shuttle vector, Apr, TRP3 Invitrogen
pGEM-T-FPS1 1,941-kbp PCR fragment containing FPS1 cloned in pGEM-T This study
pUC18 E. coli cloning vector, Apr Ref. 46
pUC18-LEU2 3.0-kbp BglII fragment containing LEU2 ligated into BglII site of pUC18 This study
pX-G-ev1 Cloning vector Ref. 26
pX-G-ev1-AQP9 Rattus norvegicus AQP9 gene cloned into the BglII site of pXG-ev1 This study
pAQP9 1.1-kbp HindIII–KpnI fragment containing AQP9 cloned into HindIII–KpnI-digested pYES3 This study
pX-G-ev1-AQP7 Mus musculus AQP7 gene cloned into the BglII site of pXG-ev1 This study
pAQP7 1.2-kpb EcoRI fragment containing AQP7 cloned into EcoRI-digested pYES3 This study
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at 30°C in either YPG medium or SD medium with 2% galactose
in place of glycerol. The cells were harvested, washed twice with
degassed transport buffer consisting of 75 mM Hepes, 150 mM
KCl, and 1 mM MgCl2 (pH 7.3), and suspended to a density of
2  109 cellsml in the same buffer, all at 4°C. To initiate the
assay, 0.1 ml of cells was diluted with 0.9 ml of transport buffer
containing 0.1 M glucose. After 30 min at 30°C, Na273AsO2 or
K(125Sb)tartrate were added to a final concentration of 5 M.
When used as an inhibitor, glycerol was added to a final
concentration of 200 mM 20 min before the radioactive metal-
loid. Portions (0.1 ml) were withdrawn at intervals and filtered
through nitrocellulose filters (0.2-m pore size; Whatman). The
filters were washed with 5 ml of room temperature transport
buffer and dried, and the radioactivity was quantified in liquid
scintillation counter. Na273AsO2 and K(125Sb)tartrate were pre-
pared by reduction of radioactive arsenate or antimonate (25).
73As was obtained from Los Alamos National Laboratories.
125Sb was purchased from New England Nuclear.
Transport in Xenopus laevis oocytes was performed as de-
scribed (26). Plasmids pXG-ev1-AQP7 and pXG-ev1-AQP9
were linearized with NotI and XbaI, respectively. Capped cRNAs
were synthesized in in vitro reactions by using the linearized
plasmids. Oocytes from Xenopus laevis were defolliculated and
injected with 5 ng of AQP7 cRNA, 25 ng of AQP9 cRNA, or 50
nl of water. They were then incubated at 18°C for 3 d in Barth’s
solution (26). For transport assays the oocytes were incubated
with 0.5 ml of Barth’s solution containing 3 M 73As(OH)3.
After 90 sec the assay solution was removed, and the oocytes
were washed with same solution without labeled arsenite. The
oocytes were then solubilized with 0.2 ml of 10% SDS, and
radioactivity was quantified in liquid scintillation counter.
Immunological Detection of AQP7 and AQP9 Expression. Membranes
for immunoblot analysis of AQP7 and AQP9 expression were
prepared as described previously (12). The membranes were
analyzed for AQP7 and AQP9 expression by PAGE and immu-
noblotting. Samples were dissolved in 0.1 ml of SDS sample
buffer, incubated for 2 h at room temperature and analyzed by
SDSPAGE (27) by using a 12% polyacrylamide gel. Proteins
were electrophoretically transferred to a nitrocellulose mem-
brane (0.2-m pore size) and immunoblotted overnight at 12 mV
and 4° C with an Ab directed against either AQP7 or AQP9
(Alpha Diagnostic, San Antonio) at a dilution of 1:5,000 or
1:4,000, respectively. A chemiluminescent assay was used to
detect the antigen-Ab reaction. The filter was incubated with
10 ml of the enhanced chemiluminescence solution (New
England Nuclear) and exposed on x-ray film for 10 sec at room
temperature.
Results
AQP9 Complements the Metalloid Resistance Phenotype of an fps1
Strain of S. cerevisiae. Two microbial aquaglyceroporins have been
shown to facilitate metalloid uptake, GlpF in E. coli (13) and
Fps1p in S. cerevisiae (18). The most closely related mammalian
homologs to the two microbial proteins are AQP7 and AQP9. R.
norvegicus AQP9 is 32% identical and 52% similar to Fps1p. M.
musculus AQP7 is slightly more distant, with 28% identity and
44% similarity to Fps1p. Both mammalian proteins are more
distant from the prokaryotic aquaglyceroporin, but AQP7 and
AQP9 are more closely related to each other, sharing 52%
identity and 68% similarity.
The ability of AQP7 and AQP9 to substitute for Fps1p in yeast
was examined. Strain MG102 (acr3 ycf1) is hypersensitive to
metalloids because the genes for Acr3p and Ycf1p have been
deleted (12). MG102 was used to construct a triple fps1 acr3
ycf1 strain, HD9. The two mammalian cDNAs were cloned into
the yeast expression vector pYES3 under control of the GAL4
promoter, and galactose-dependent expression was examined.
When pAQP9 was introduced into strain HD9, cell membranes
contained bands at 25 and 50 kDa when induced with galactose
(Fig. 1). As is often observed (16), the immunologically reacting
bands migrated slightly faster than expected for the mass of a
monomer and dimer of the 32-kDa AQP9. In contrast, no
immunologically reacting material was found in membranes
from cells transformed with pAQP7 (data not shown).
Compared to strain MG102, strain HD9 was resistant to
arsenite (Fig. 2A). HD9 was also relatively resistant to antimo-
nite (Fig. 2B) but not arsenate (Fig. 2C) or cadmium (Fig. 2D).
This result is consistent with the proposal that Fps1p facilitates
metalloid uptake in yeast (18). Strain HD9 was used as the host
for analysis of AQP7 and AQP9 function. Expression of AQP9
reversed the arsenite (Fig. 2 A) and antimonite (Fig. 2B) resis-
tance phenotype of strain HD9. Reversal of the fps1 phenotype
by expression of AQP9 from the GAL4 promoter required
induction with galactose (Fig. 2 A). AQP9 had no effect on
sensitivity of strain HD9 to either arsenate (Fig. 2C) or cadmium
(Fig. 2D). On the whole, these results clearly demonstrate that
AQP9 can replace the function of Fps1p in trivalent metalloid
sensitivity. Even though there was not enough AQP7 produced
to be detected by Western blotting, it was possible that there was
enough to complement the FSP1 deletion. However, introduc-
tion of AQP7 on a plasmid had no effect on resistance to either
arsenite or antimonite.
AQP9 Facilitates Uptake of 73As(OH)3 and 125Sb(OH)3 in S. cerevisiae.
The ability of AQP9 to transport arsenite into yeast also was
investigated. Strain MG102 lacks arsenite extrusion and, hence,
accumulates arsenite (12). When FPS1 was deleted in this
background, the rate of transport of 73As(III) was reduced (Fig.
3A). These results demonstrate that Fps1p facilitates uptake of
73As(OH)3, which should be the predominant form at neutral
pH. Because aquaporins are channels and do not exhibit energy-
dependent concentration of solutes, the apparent accumulation
probably reflects intracellular binding of arsenite. Cells express-
ing AQP9 accumulated more 73As(OH)3 than the parental strain
Fig. 1. Expression of AQP9 in membranes of S. cerevisiae. Membranes were
prepared from cells of strain HD9 or HD9 pAQP9 grown in the absence or
presence of 2% galactose, as indicated. Membrane proteins were separated
by SDSPAGE and immunoblotted with anti-AQP9 as described in Materials
and Methods.








MG102. Transport of 73As(III) and 125Sb(III) (see below) con-
sistently exhibited a lag, with increased intracellular arsenite
observed at later time points, but the basis for this observation
is unknown. Glycerol is the primary substrate of AQP9, so
competition between glycerol and arsenite would be expected,
and 0.2 M glycerol reduced the uptake of 5 M arsenite (Fig.
3B). In growth assays, 0.2 M glycerol also produced a small
reversal of the AQP9-related arsenite sensitivity (data not
shown).
Transport of Sb(III) has been inferred from in vivo resistance
assays, but direct measurement has not been possible because of
the unavailability of radioactive antimony. For this study 125Sb
was custom synthesized. Cells of the triple deletion fps1 acr3
ycf1 strain HD9 exhibited low rates of transport of 125Sb(OH)3
compared to HD9 expressing AQP9, demonstrating that AQP9
facilitates transport of Sb(III) as well as As(III) (Fig. 3C).
Both AQP7 and AQP9 Facilitate 73As(OH)3 Permeability in Xenopus
Oocytes. Because AQP7 was not expressed in yeast, the ability of
the aquaglyceroporins to increase arsenite permeability in Xe-
nopus oocytes was examined. Water, AQP7, or AQP9 cRNA
prepared in vitro was microinjected into Xenopus oocytes. Either
aquaglyceroporin increased the uptake of 73As(OH)3 10-fold
(Fig. 4). These results suggest that both aquaglyceroporins can
facilitate uptake of arsenite.
Discussion
Aquaglyceroporins have been shown to facilitate metalloid
uptake in both E. coli (13) and S. cerevisiae (18). Without these
transporters, cells are unusually resistant to arsenite andor
antimonite. The closest mammalian homologs to E. coli GlpF
and yeast Fsp1p are AQP7 and AQP9. In this report, we
demonstrate that AQP9 can transport arsenite into yeast. AQP9
exhibits the broadest solute permeation, including carbamides,
polyols, purines, and pyrimidines (20). AQP7, which is expressed
in testis (28) and kidney (29) and has a narrower range of
substrate specificity, transporting primarily glycerol and urea
(28), was not expressed in yeast. However, in Xenopus laevis
oocytes AQP7 and AQP9 both increased arsenite permeability.
These results indicate that both AQP7 and AQP9 may be routes
of arsenite uptake into mammalian cells (Fig. 5).
The structure of aquaporin AQP1 (30, 31) and aquaglycero-
porin GlpF (32) have recently been determined at atomic
Fig. 2. AQP9 functionally complements the metalloid sensitivity of S. cer-
evisiae fps1. Growth was measured in liquid SD minimal medium with 2%
galactose (or, if repressed, glucose) in the presence of the indicated concen-
trations of sodium arsenite (A), potassium antimonyl tartrate (B), sodium
arsenate (C), or cadmium chloride (D). Strains were: ■ , MG102 (acr3 ycf1);
E, HD9 ( fps1 acr3 ycf1) pYES3; F, HD9 pAQP7 (induced); , HD9 pAQP9
(induced); and ƒ, HD9 pAQP9 (repressed).
Fig. 3. AQP9 facilitates uptake of 73As(OH)3 and 125Sb(OH)3. (A) Transport of
73As(OH)3. (B) Inhibition of 73As(OH)3 uptake by glycerol. (C) Transport of
125Sb(OH)3. Strains were: F, HD9 pYES3; E, HD9 pAQP9; , HD9 pAQP7; ƒ,
MG102; and ■ , HD9 pAQP9  0.2 M glycerol.
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resolution, and the spacing at the narrowest region of the pore
(the aromaticarginine ring) is significantly wider in the aqua-
glyceroporin. Molecular dynamics simulation may now reveal the
permeation mechanism for metalloid transport by AQP7 and
AQP9. Arsenite and antimonite are commonly considered oxya-
nions. Indeed, transport of arsenite by the bacterial ArsB carrier
is driven by the membrane potential, suggesting anionic sub-
strates (33, 34). However the trivalent arsenic and antimony
acids have pKa values of 9.2 and 11.8, respectively, so that at
neutral pH they would be primarily present in solution as neutral
species, As(OH)3 or Sb(OH)3. We predict that these neutral
polyhydroxylated species have sufficient molecular similarity to
glycerol to be substrates of aquaglyceroporins.
Arsenic is classified as a carcinogen by the Environmental
Protection Agency (1). Possible mechanisms of carcinogenesis
include genetic instability resulting from inhibition of telomerase
transcription (35) or by acting as a cocarcinogen to inhibit DNA
repair (36). Exposure to arsenic in drinking water is associated
with increased risk of multiple cancers. According to the Natural
Resources Defense Council, millions of Americans are consum-
ing tap water every day that poses unacceptable cancer risks
(http:www.nrdc.orgwaterdrinkingqarsenicasp). Over
56 million Americans in the 25 reporting states consumed water
from systems containing arsenic at levels presenting a potentially
fatal cancer risk. Based on reports by the U.S. National Research
Council (37), the Environmental Protection Agency has
amended the Safe Drinking Water Act to lower the standard for
arsenic in drinking water from 50 to 10 gliter; however these
standards are based on the assumption that individuals respond
uniformly to arsenic. Uniform arsenic uptake is very unlikely
because levels of rat AQP9 expression in liver are known to
exhibit wide variations because of age, gender, and nutritional
status (ref. 38; J.M.C. and P.A., unpublished data). Thus,
humans would be expected to respond differently to arsenic in
the water supply, and safety standards need to reflect the
likelihood that some individual are at higher risk for toxicity.
Most of the epidemiological studies have been conducted in
countries such as Taiwan, Bangladesh, and Chile, where arsenic
exposure is endemic (39, 40). Chronic effects of arsenic in the
water supply include skin hyperpigmentation and keratoses of
the hands and feet that frequently progress to skin cancers. In
approximately 10% of these cases, exposure is associated with a
very high incidence of lung, bladder, and other cancers. How-
ever, there is considerable variation in individual responses to
arsenic. Some family members in arsenic-contaminated regions
of Bangladesh exhibit acute arsenicosis and various forms of
cancer, whereas other siblings show few or no adverse effects.
Knowledge of the aquaglyceroporin status of these individuals,
including DNA sequence and levels of expression, could illumi-
nate reasons for these variations because individuals with in-
creased expression of AQP7 or AQP9 may be more sensitive to
environmental arsenic. Thus, the levels of AQP7 andor AQP9
expression may be a biomarker for arsenic exposure.
AQP9 is primarily expressed in human lung, liver, and leuko-
cytes (41). Interestingly, liver is an organ where arsenite toxicity
is found, and some malignancies of the leukocyte lineage re-
spond to arsenite chemotherapy. A century ago, arsenic was
recommended as an antileukemic agent; however its use was
abandoned because of toxicity. More recently, arsenic trioxide,
the anhydrous form of As(OH)3 (Trisenox, Cell Therapeutics,
Seattle) has been approved as a chemotherapeutic agent for the
treatment of acute promyelocytic leukemia (39, 40). Our study
suggests that AQP9 may be responsible for the chemotherapeu-
tic effects of arsenite by facilitating diffusion of the agent into the
leukemia cells. As has been found with most chemotherapeutic
Fig. 4. 73As(OH)3 permeability in Xenopus oocytes expressing AQP7 or AQP9.
Oocyte transport of 73As(OH)3 was assayed for 90 sec as described in Materials
and Methods. Each bar represents the average of three assays. Oocytes were
injected with H2O, AQP7 cRNA, or AQP9 cRNA.
Fig. 5. Metalloid transporters in prokaryotes and eukaryotes. The model shows a comparison of arsenite transport pathways in E. coli (A), S. cerevisiae (B), and
a generalized mammalian cell (C). In each of three, arsenite uptake is facilitated by an aquaglyceroporin: the bacterial GlpF, the yeast Fps1p, or the mammalian
AQP7 or AQP9. In E. coli, arsenite is extruded from the cytosol by the ArsAB pump. In yeast, arsenite extrusion from the cytosol is catalyzed by Acr3p or into the
vacuole by the ATP-coupled Ycf1p pump as As(GS)3. In mammalian cells, various isoforms of the multidrug resistance associate protein (MRP), a Ycf1p homolog,
pump out As(GS)3.








agents, resistance eventually arises with continued use (42), and
arsenic trioxide resistance will eventually occur. Emergence of
AQP9 negative clones of promyelocytic leukemia could signal
the need to change therapy. Conversely, individuals with in-
creased expression of AQP9 in liver may have altered sensitivity
to arsenic trioxide. In a recent study of 11 newly diagnosed and
47 relapsed acute promyelocytic leukemia patients treated with
arsenic trioxide, seven of the newly diagnosed patients exhibited
hepatic toxicity (including two deaths), whereas the relapsed
patients had only minor reactions (43). It will be of considerable
interest to examine the expression of AQP9 in such patients to
determine whether there is a correlation between higher AQP9
levels in the promyelocytic leukemia cells or in the liver and
increased sensitivity to arsenic trioxide therapy or toxicity. If so,
the AQP9 status of patients with promyelocytic leukemia may be
predictive of the success of arsenic trioxide treatment.
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